239 related articles for article (PubMed ID: 30666297)
1. BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.
Tessoulin B; Papin A; Gomez-Bougie P; Bellanger C; Amiot M; Pellat-Deceunynck C; Chiron D
Front Oncol; 2018; 8():645. PubMed ID: 30666297
[TBL] [Abstract][Full Text] [Related]
2. BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic.
Lin VS; Xu ZF; Huang DCS; Thijssen R
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198338
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
4. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
[TBL] [Abstract][Full Text] [Related]
5. Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status.
Dolnikova A; Kazantsev D; Klanova M; Pokorna E; Sovilj D; Kelemen CD; Tuskova L; Hoferkova E; Mraz M; Helman K; Curik N; Machova Polakova K; Anděra L; Trněný M; Klener P
Blood Adv; 2024 May; ():. PubMed ID: 38713893
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.
Klanova M; Klener P
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290241
[TBL] [Abstract][Full Text] [Related]
7. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
8. BH3 Mimetics in Hematologic Malignancies.
Klener P; Sovilj D; Renesova N; Andera L
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576319
[TBL] [Abstract][Full Text] [Related]
9. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies.
Yue X; Chen Q; He J
Cancer Cell Int; 2020 Oct; 20(1):524. PubMed ID: 33292251
[TBL] [Abstract][Full Text] [Related]
10. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Kitsoulis P; Kanavaros P
Anticancer Res; 2004; 24(5A):3081-8. PubMed ID: 15517919
[TBL] [Abstract][Full Text] [Related]
11. Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.
Ngoi NYL; Choong C; Lee J; Bellot G; Wong ALA; Goh BC; Pervaiz S
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32131385
[TBL] [Abstract][Full Text] [Related]
12. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
13. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D; Jorda R; Kupcova K; Senavova J; Dolnikova A; Pokorna E; Kazantsev D; Nozickova K; Sovilj D; Bellanger C; Chiron D; Andera L; Krystof V; Strnad M; Helman K; Klanova M; Trneny M; Havranek O; Klener P
Exp Hematol Oncol; 2024 Mar; 13(1):34. PubMed ID: 38528594
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.
Rys RN; Wever CM; Geoffrion D; Goncalves C; Ghassemian A; Brailovski E; Ryan J; Stoica L; Hébert J; Petrogiannis-Haliotis T; Dmitrienko S; Frenkiel S; Staiger A; Ott G; Steidl C; Scott DW; Sesques P; Del Rincon S; Mann KK; Letai A; Johnson NA
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670870
[TBL] [Abstract][Full Text] [Related]
15. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
16. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biological Activity of Scyllatoxin-Based BH3 Domain Mimetics Containing Two Disulfide Linkages.
Arachchige D; Holub JM
Protein J; 2018 Oct; 37(5):428-443. PubMed ID: 30128635
[TBL] [Abstract][Full Text] [Related]
18. Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia.
Richter A; Lange S; Holz C; Brock L; Freitag T; Sekora A; Knuebel G; Krohn S; Schwarz R; Hinz B; Murua Escobar H; Junghanss C
Cell Death Discov; 2022 Jul; 8(1):302. PubMed ID: 35778418
[TBL] [Abstract][Full Text] [Related]
19. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
20. Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis.
Han J; Modha D; White E
Oncogene; 1998 Dec; 17(23):2993-3005. PubMed ID: 9881701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
